Bayer will take another look at the use of glyphosate in lawn and garden products, including the possibility of new active ingredients to replace it, the company said in response to a court order rejecting a plan to address potential future Roundup litigation.
A federal judge has rejected a $2 billion plan put forth by Bayer to address a proposed class of plaintiffs who have been exposed to Roundup but have not filed lawsuits against the company, saying the purported benefits of the proposed settlement have been exaggerated.
A federal judge has posed some pointed questions for a hearing Wednesday where he will consider whether to grant preliminary approval to a Bayer-proposed settlement for a so-called “futures class” of plaintiffs who contract non-Hodgkin lymphoma.
Bayer has agreed with plaintiffs’ counsel on a plan the company said is “designed to manage and resolve future Roundup cases,” a key component of settling thousands of claims against the company over exposure to the widely used herbicide.
Bayer and attorneys for a proposed class of potential future Roundup plaintiffs will go back to the drawing board after a federal judge expressed skepticism over the legality and fairness of their proposed settlement.
Bayer has announced “a series of agreements that will substantially resolve major outstanding Monsanto litigation,” including payments of up to $10.9 billion to settle current and future Roundup claims against the company and $400 million to settle dicamba drift damage complaints.
Lawyers for Monsanto and Dewayne Lee Johnson squared off Tuesday before a California appeals court over whether he should be compensated for exposure to Roundup that he claims caused his non-Hodgkin lymphoma.
A trial in St. Louis involving a plaintiff who alleges exposure to Roundup caused her non-Hodgkin lymphoma has been delayed indefinitely, leading to speculation that Bayer and plaintiffs’ lawyers need the time to work out a settlement.